Robert Visit 3: Second follow-up visit for residual vascular risk reduction

Title:

Robert Visit 3: Second follow-up visit for residual vascular risk reduction
Topic: Cardiology
Relevant Terms: CVD Risk Reduction, Diabetes, Dyslipidemia, Hypertension, Macrovascular Risk, Microvascular Risk, Residual Vascular Risk
Primary Audience: Primary Care Physicians
Launch Date: 05-Jan-10
Credits: 1 AMA PRA Category 1 Credit™
Expiration Date: 04-Jan-11

Learning Objectives

After completion of this activity, participants should be better able to:

  1. Identify patient-related factors that impact the success of residual risk reduction efforts
  2. Apply treatment guidelines to specific residual risk reduction patient scenarios
  3. Utilize weight, BMI and lipid parameters to stratify patients into various risk classifications
  4. Identify risk factors for the development of type 2 diabetes
  5. Utilize biomarkers to assess and manage residual vascular risk
  6. Apply various pharmacologic treatments to reduce residual vascular risk

Faculty

Michel P. Hermans MD
Assistant Professor, Endocrinology & Nutrition
Cliniques universitaires St-Luc, Université catholique de Louvain
Brussels, Belgium Jesús Millán Núñez-Cortés, MD, PhD, PharmD, FACP
Director of Cardiovascular Risk Unit
Hospital General Universitario Gregorio Marañón
Madrid, Spain Alberto Zambon MD, PhD
Assistant Professor of Medicine
School of Medicine, Department of Medical and Surgical Sciences
Clinica Medica 1° - University of Padua, Italy
Assistant Professor of Medicine
Division of Metabolism, Endocrinology, and Nutrition, University of Washington
Seattle, USA
DISCLOSURE POLICY STATEMENT It is the policy of Cardiovascular Institute of the South to ensure balance, independence, objectivity, and scientific rigor in all its sponsored educational programs. All those in control of the content are required to disclose to the activity audience any significant financial interest, related off-labeled use of products or other relationship (1) with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity.

Michel Hermans, MD reports that he has received honoraria from GlaxoSmithKline, Pfizer, Solvay, AstraZeneca, Roche, sanofi-aventis, Nycomed, Merck, and Menarini. He receives consulting fees from Lilly, Bayer, AstraZeneca, GlaxoSmithKline, and sanofi-aventis.
Jesus Millan Nunez-Cortes, MD reports that he has received honoraria and consulting fees from Solvay, Pfizer, AstraZeneca and Merck Sharp and Dohme.
Alberto Zambon, MD reports that he has received honoraria and consulting fees from AstraZeneca, sanofi-aventis, Bayer, Solvay and Abbott.

Peer Reviewer: Qanta Ahmed, MD has disclosed that she has no relevant financial relationship with any commercial interests.

DISCLOSURE OF DISCUSSIONS OF OFF-LABEL AND INVESTIGATIONAL USES OF DRUGS This activity may include discussion of therapeutic agents that are not approved for use in the United States.

DISCLOSURE ATTESTATION Each of the contributing physicians listed above has attested to the following: 1) that the relationships/affiliations noted will not bias or otherwise influence his or her involvement in this activity; 2) that stated practice recommendations that may be relevant to the companies with whom they have relationships/affiliations will be supported by the best available evidence or, absent evidence, will be consistent with generally accepted medical practice; and 3) that all reasonable clinical alternatives will be discussed when making practice recommendations.

DISCLAIMER The information presented in any case presented in this activity is only one approach to patient care, and good clinical judgment should be used to design a medication regimen tailored to each patient's individual characteristics. Clinicians have implied responsibility for the newly acquired information to enhance patient outcomes and their own professional development. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients' conditions and possible contraindications or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

CREDIT DESIGNATION The Cardiovascular Institute of the South designates this educational activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Each physician should claim only those credits that he/she spent on the activity.

ACCREDITATION STATEMENT This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through The Cardiovascular Institute of the South. The Cardiovascular Institute of the South is accredited by the ACCME to provide continuing medical education for physicians.

LEARNER BILL OF RIGHTS The Cardiovascular Institute of the South (CIS) recognizes that you are a life-long learner who has chosen to engage in continuing medical education to identify or fill a gap in knowledge, skill, or performance. As part of CIS's duty to you as a learner, you have the right to expect that your continuing medical education experience with CIS will include: Content that: Promotes improvements or quality in healthcare. Is valid, reliable, and accurate. Offers balanced presentations that are free of commercial bias for or against a product/service. Is vetted through a process that resolves any conflicts of interests of planners and faculty. Is driven and based on learning needs, not commercial interests. Addresses the stated objectives or purpose. Is evaluated for its effectiveness in meeting the identified educational need.A learning environment that:Supports learners' ability to meet their individual needs. Respects and attends to any special needs of the learners. Respects the diversity of groups of learners. Is free of promotional, commercial, and/or sales activities.Disclosure of:Relevant financial relationships planners, instructors, and authors have with commercial interests related to the content of the activity. Commercial support (funding or in-kind resources) of the activity.

ACKNOWLEDGEMENT This activity is supported by an unrestricted educational grant from the Residual Risk Reduction Initiative (R3i).
To Obtain CME Credits This activity includes text, graphics, and may include multi-media features. Click on all of the medical education activity links and review the content presented.
  1. Read, complete, and submit answers to the examination and evaluation questions online.
  2. You must score with a 70% or higher to receive credit for this activity.
  3. Once you have successfully completed the examination & evaluation, a certificate will be automatically generated.

COURSE VIEWING REQUIREMENTS
PC
Internet Explorer (v6 or greater), or Firefox		 MAC
Safari

Release Date: January 5, 2010
Expiration Date: January 4, 2011